ST. PAUL, Minn., March 13, 2017 /PRNewswire/ -- EnteroMedics Inc.
(NASDAQ:ETRM), the developer of medical devices using neuroblocking
technology to treat obesity, metabolic diseases and other
gastrointestinal disorders, today announced that its
vBloc® Neurometabolic Therapy for the treatment of
obesity will be featured on the March
14 episode of the Emmy Award-winning syndicated daytime talk
show The Doctors. Frank Chae,
MD, FACS, Chief Surgeon and Head of the Bariatric Center at Sky
Ridge Medical Center in Colorado
and Cindy Hudak, one of his patients
who received vBloc Therapy will discuss the benefits of vBloc
Therapy and Cindy's personal story of battling obesity. The
Doctors, on air since 2008, offers the most timely, topical and
practical health, wellness and lifestyle information on daytime
television. To find a station where The Doctors airs, please
visit http://photos.thedoctorstv.com/when-its-on/
"The Doctors is a well-respected television show many
people watch in order to learn about different medical conditions,
including obesity, and the latest innovative treatments available
to them," said Dan Gladney,
EnteroMedics President, Chief Executive Officer and Chairman of the
Board. "We are thrilled The Doctors has decided to feature
vBloc Therapy and hope patients who see the segment and are
appropriate for its use will take action and contact their doctor
to learn more about its benefits. I also want to applaud vBloc
patient Cindy Hudak for her great
success to date and thank her for sharing her story."
vBloc Therapy is approved for use in helping with weight loss in
people aged 18 years and older who are obese, with a BMI of 40 to
45 kg/m2, or a BMI of 35 to 39.9 kg/m2 with a
related health condition such as Type 2 diabetes, high blood
pressure, high cholesterol levels or obstructive sleep apnea who
have had a poor response to trying to lose weight under supervision
in the last 5 years.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the
development and commercialization of its neuroscience based
technology to treat obesity and metabolic diseases.
vBloc® Neurometabolic Therapy, delivered by a
pacemaker-like device called the vBloc® System, is
designed to intermittently block the vagus nerves using
high-frequency, low-energy, electrical impulses.
EnteroMedics' vBloc® System has received U.S.
Food and Drug Administration approval and CE Mark.
Information about the vBloc® System and
vBloc® Neurometabolic Therapy
You should not have an implanted vBloc® System
if you have cirrhosis of the liver, high blood pressure in the
veins of the liver, enlarged veins in your esophagus or a
significant hiatal hernia of the stomach; if you need magnetic
resonance imaging (MRI); if you have a permanently implanted,
electrical medical device; or if you need a diathermy procedure
using heat. The most common related adverse events that were
experienced during clinical study of the vBloc System included
pain, heartburn, nausea, difficulty swallowing, belching, wound
redness or irritation, and constipation.
Talk with your doctor about the full risks and benefits of vBloc
Therapy and vBloc System. For additional prescribing information,
please visit www.enteromedics.com.
If you are interested in learning more about vBloc
Neurometabolic Therapy, please visit www.vbloc.com or call
1-800-MY-VBLOC.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements
about EnteroMedics Inc. Our actual results could differ
materially from those discussed due to known and unknown risks,
uncertainties and other factors including our limited history of
operations; our losses since inception and for the foreseeable
future; our limited commercial sales experience with our
vBloc® System for the treatment of obesity in the
United States or in any foreign market other
than Australia and the European Community; our ability to
maintain compliance with the Nasdaq continued listing requirements;
our ability to commercialize our vBloc® System; our
dependence on third parties to initiate and perform our clinical
trials; the need to obtain regulatory approval for any
modifications to our vBloc® System; physician adoption
of our vBloc® System and vBloc®
Neurometabolic Therapy; our ability to obtain third party coding,
coverage or payment levels; ongoing regulatory compliance; our
dependence on third party manufacturers and suppliers; the
successful development of our sales and marketing capabilities; our
ability to raise additional capital when needed; international
commercialization and operation; our ability to attract and retain
management and other personnel and to manage our growth
effectively; potential product liability claims; potential
healthcare fraud and abuse claims; healthcare legislative reform;
and our ability to obtain and maintain intellectual property
protection for our technology and products. These and additional
risks and uncertainties are described more fully in the Company's
filings with the Securities and Exchange Commission,
particularly those factors identified as "risk factors" in the
annual report on Form 10-K filed March 8, 2017. We are
providing this information as of the date of this press release and
do not undertake any obligation to update any forward-looking
statements contained in this document as a result of new
information, future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/enteromedics-vbloc-neurometabolic-therapy-featured-on-the-doctors-tv-show-300422611.html
SOURCE EnteroMedics Inc.
